Isolated sulfite oxidase deficiency: a founder mutation. by Mhanni, Aizeddin A et al.
Western University 
Scholarship@Western 
Paediatrics Publications Paediatrics Department 
12-1-2020 
Isolated sulfite oxidase deficiency: a founder mutation. 
Aizeddin A Mhanni 
Cheryl R Greenberg 
Elizabeth L Spriggs 
Ronald Agatep 
Reena Ray Sisk 
See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub 
 Part of the Pediatrics Commons 
Citation of this paper: 
Mhanni, Aizeddin A; Greenberg, Cheryl R; Spriggs, Elizabeth L; Agatep, Ronald; Sisk, Reena Ray; and 




Aizeddin A Mhanni, Cheryl R Greenberg, Elizabeth L Spriggs, Ronald Agatep, Reena Ray Sisk, and Chitra 
Prasad 
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/556 
Isolated sulfite oxidase deficiency:
a founder mutation
Aizeddin A. Mhanni,1 Cheryl R. Greenberg,1,2 Elizabeth L. Spriggs,1,2
Ronald Agatep,2 Reena Ray Sisk,3 and Chitra Prasad4
1Department of Pediatrics and Child Health, 2Department of Biochemistry andMedical Genetics, University of
Manitoba,Winnipeg, Manitoba R3A 1S1, Canada; 3Saskatoon Health Authority, Saskatoon S7K 0M7, Canada;
4London Health Sciences Centre, Western University, London, Ontario N6A 5A5, Canada
Abstract Isolated sulfite oxidase deficiency is a rare autosomal recessive inborn error of sul-
fur metabolism. Clinical features generally include devastating neurologic dysfunction,
ectopia lentis, and increased urinary excretion of sulfite, thiosulfate, and S-sulfocysteine.
Missed diagnosis is not unusual because of variability in the sensitivity of the urinary sulfite
and thiosulfate screening test. We present clinical, biochemical, and molecular data on two
unrelated patients with isolated sulfite oxidase deficiency. The two patients belong to an
Indigenous genetic isolate in Manitoba, Canada. Both patients (one male and one female,
both now deceased) developed neonatal seizures and demonstrated progressive neurode-
velopmental delay. Based on increased urinary excretion of sulfite, thiosulfate, and S-sulfo-
cysteine and normal serum uric acid levels, sulfite oxidase deficiency was suspected. Both
patients have a homozygous 4-bp deletion, 1347–1350delTTGT in the sulfite oxidase gene
(SUOX), predicting a premature termination of the sulfite oxidase protein leading to ab-
sence of the carboxy-terminal third portion of the protein. This domain contains most of
the contact sites essential for enzyme dimerization. This deletionmutation resulted in sulfite
oxidase deficiency with early-onset severe clinical phenotype.
CASE PRESENTATION
The clinical and biochemical data on the two patients are presented in Tables 1 and 2,
respectively.
TECHNICAL ANALYSIS
Genomic DNA was isolated from cultured fibroblasts and/or blood samples, and the gene
encoding SUOX was amplified by polymerase chain reaction (PCR) using standard condi-
tions. PCR primers spanning the entire coding region (CCTCAAGGATCTGCATTCAGGCC
and AAGGGGTGGAGGTGGCTCCTTTCC) were included at a concentration of 1 µmolar,
and the reaction was cycled for 30 sec at 55°, for 5 min at 68°, and for 30 sec at 95° for a total
of 35 cycles. The entire reaction mixture was run on an agarose gel and the band at ∼2.4 kb,
corresponding to the sulfite oxidase gene with its single intron, was extracted from the gel
and sequenced in both the forward and reverse directions. AutomatedDNA sequencing was
performed at the Duke University Comprehensive Cancer Center facility using a
PerkinElmer/ABI 377 DNA Sequencer and Big Dye sequencing chemistry. Numbering of nu-
cleotides is based on the cDNA sequence, with the A of the ATG initiator methionine codon
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denoted nucleotide +1. Numbering of the amino acids is also from the initiator methionine,
which is the first amino acid in the 22-residue leader sequence of sulfite oxidase.
VARIANT INTERPRETATION
Both patients have a homozygous 4-bp deletion, 1347–1350delTTGT in the sulfite oxidase
gene (SUOX), predicting a premature termination of the sulfite oxidase protein leading to
absence of the carboxy-terminal third portion of the protein. This domain contains most
of the contact sites essential for enzyme dimerization. The parents are heterozygous for
this variant. This novel variant in SUOX likely is a founder mutation, given its presence in
two unrelated Indigenous children from the same genetic isolate (Table 3).
Isolated sulfite oxidase deficiency (MIM 272300) is an autosomal recessive disorder
caused by mutations in the sulfite oxidase gene (SUOX), GenBank accession number
AY056018. The gene is located on Chromosome 12, in the region of 12q13.2, and the cod-
ing sequence contains a single intron. The gene product, sulfite oxidase, is a molybdohemo-
protein comprised of 466 amino acids. It is synthesized with a 22-residue leader sequence
that directs it to the mitochondrial intermembrane space. The mature protein lacks this pre-
sequence. The native enzyme is a dimer of identical subunits, each of which contains three
domains—the amino-terminal heme domain, the central molybdenum domain, and a car-
boxy-terminal domain with key residues at the dimer interface (Johnson and Rajagopalan
1976; Kisker et al. 1997). The enzyme catalyzes the oxidation of sulfite to sulfate, the terminal
reaction in the degradation of sulfur-containing amino acids, and transfers the electrons de-
rived from substrate oxidation to cytochrome c on the inner mitochondrial membrane.
Sulfite oxidase deficiency is classically characterized by severe neurological symptoms
including seizures, often refractory to anticonvulsant medications, and rapidly progressing










1 First week F Intractable seizures, severe
developmental delay, spastic
quadriplegia
Not assessed Negative Indigenous Deceased at
9 yr
2 5 d M Lethargy, hypotonia, severe
developmental delay,
intractable seizures
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to an encephalopathic state. A significant proportion of patients develop complete or partial
ectopia lentis. Althoughmilder cases have been described, in the classic presentation, death
occurs at an early age, and none of the treatments tested to date improved the clinical out-
come (Johnson and Duran 2001). The preliminary diagnosis is made by elevated urinary sul-
fites, increased excretion of thiosulfate, increase in S-sulfocysteine, and normal serum uric
acid, xanthine, and hypoxanthine. Confirmatory diagnosis is made by measuring sulfite ox-
idase activity in liver or fibroblasts or identifying a disease-causing mutation in SUOX. To
date there have been 21 missense/nonsense mutations, seven small deletions, and one
small insertion in SUOX reported in individuals with isolated sulfite oxidase deficiency
(HGMD). The mutation identified here resulted in severe sulfite oxidase deficiency with early
onset and severe clinical manifestations.
SUMMARY
It is important to consider isolated sulfite oxidase deficiency/molybdenum cofactor defi-
ciency particularly when dealing with severe seizures and developmental delay in infancy.
Screening of fresh urine for sulfites is a simple test but has false positives and false negatives.
Urine for thiosulfate can be falsely positive with sulfur containing antibiotics and some anti-
convulsants. Urine screening for S-sulfocysteine is more reliable. Uric acid is normal in isolat-
ed sulfite oxidase deficiency as compared to molybdenum cofactor deficiency, in which it is
usually low. Cranial MRI and EEG are usually abnormal although not diagnostic. The muta-
tion described here of a 4-bp deletion 1347–1350delTTGT in SUOX, in two unrelated
Indigenous patients predicts a premature termination of the sulfite oxidase protein.
Carrier screening for this deletionmutation will be offered to the patients’ extended families.
ADDITIONAL INFORMATION
Data Deposition and Access
The variant has been submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and can
be found under accession number SCV001450523.
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Verbal consent for publication from the families was obtained. We did not require Research
Ethics Board approval as the molecular testing reported in this manuscript was done as part
of standard clinical care.
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